Rockland Trust Co. Has $34.27 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Rockland Trust cut its stake in Thermo Fisher by 7.6% in Q4 to 59,133 shares valued at $34.27 million, making TMO about 1.3% of its portfolio and its 20th-largest holding.
• Q4 beat: Thermo Fisher reported EPS of $6.57 vs $6.45 expected and revenue of $12.22 billion (up 7.2% YoY), with analysts forecasting roughly 23.28 EPS for the year.
• The company raised its quarterly dividend to $0.47 (annualized $1.88, yield 0.4%), and the stock carries a consensus "Moderate Buy" with an average target of $632.50.

Rockland Trust Co. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,133 shares of the medical research company's stock after selling 4,859 shares during the quarter. Thermo Fisher Scientific makes up about 1.3% of Rockland Trust Co.'s investment portfolio, making the stock its 20th largest position. Rockland Trust Co.'s holdings in Thermo Fisher Scientific were worth $34,265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of TMO. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $28,000. Highline Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after purchasing an additional 33 shares in the last quarter. Beacon Financial Strategies CORP bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Olistico Wealth LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Capital A Wealth Management LLC grew its stake in Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after buying an additional 66 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $492.07 on Wednesday. The stock has a market capitalization of $182.80 billion, a PE ratio of 27.74, a price-to-earnings-growth ratio of 2.77 and a beta of 0.96. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The company has a 50 day moving average price of $524.79 and a 200 day moving average price of $548.30. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.95 billion. During the same period last year, the firm earned $6.10 EPS. The business's revenue for the quarter was up 7.2% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.60%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company's stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company's stock.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher launched the Thermo Scientific Glacios 3 Cryo-TEM, a next‑generation 200 kV cryo‑TEM targeted at structural biology labs — a product that can expand addressable markets for high‑margin instruments and support equipment sales and service revenue growth. Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM
• Positive Sentiment: Positive investor commentary and momentum from recent quarterly results (strong EPS and revenue beat in late Jan.) have helped set expectations for a rally and a new 52‑week high, reinforcing investor confidence in execution and cash flow. Thermo Fisher Scientific (TMO) Sets Stage for Q4 Rally with Impressive Q3 Earnings and New 52-Week High
• Positive Sentiment: High‑profile endorsement: media coverage noting Jim Cramer called the company “unbelievable” has driven retail interest and contributed to the stock’s upward momentum, especially given TMO’s exposure to the booming biopharma/GLP‑1 supply chain. Thermo Fisher (TMO) Shares Up Since Jim Cramer Called the Firm “Unbelievable”
• Neutral Sentiment: Research coverage initiated at DZ Bank — adds institutional coverage and may improve liquidity and analyst visibility; impact depends on the tone of subsequent reports. Thermo Fisher Scientific NYSE: TMO Research Coverage Started at DZ Bank
• Negative Sentiment: Industry cost risk: multiple outlets cite analyst concerns that rising global helium prices (linked to geopolitical tensions) could increase operating costs for cryogenic instruments and consumables — a potential margin headwind for TMO’s instrument/service businesses. How is Thermo Fisher (TMO) Preparing to Deal With Rising Helium Prices
• Negative Sentiment: Small position trim: Beacon Investment Advisory sold 1,296 shares in Q4, shrinking its holding — a minor vote of caution but not material to TMO’s large shareholder base. Beacon Investment Advisory Services Inc. Sells 1,296 Shares of Thermo Fisher Scientific Inc. $TMO

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an "overweight" rating in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. Evercore reissued an "outperform" rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Citigroup increased their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a report on Friday, January 30th. Finally, TD Cowen cut their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $632.50.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.